Clinical Trials
52 trialsNivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
CARABELA
Spanish Breast Cancer Research Group
REVELUTION
Emory University
STEEL
RTOG Foundation, Inc.
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Neoadjuvant Ipilimumab in Prostate Cancer
M.D. Anderson Cancer Center
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
M.D. Anderson Cancer Center
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Polycystic Ovary Syndrome (PCOS) and Sleep Apnea
University of Chicago
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Alliance for Clinical Trials in Oncology
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Case Comprehensive Cancer Center
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
University of California, San Francisco
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer
University of California, San Francisco
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
M.D. Anderson Cancer Center
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
Dana-Farber Cancer Institute
Leuprolide Acetate or Goserelin Acetate Compared With Observation in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Mayo Clinic
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Melanoma Vaccine With Peptides and Leuprolide
M.D. Anderson Cancer Center
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
STREAM
Duke University
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
Beth Israel Medical Center
IAS
University of Washington
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
University of Washington
Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
Hoosier Cancer Research Network
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Masonic Cancer Center, University of Minnesota
RAD1
University of Washington
NRR
UNC Lineberger Comprehensive Cancer Center
Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Dana-Farber Cancer Institute
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Mayo Clinic
BAT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
M.D. Anderson Cancer Center
Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer
M.D. Anderson Cancer Center
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Alliance for Clinical Trials in Oncology
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Dana-Farber Cancer Institute
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
Memorial Sloan Kettering Cancer Center
Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
M.D. Anderson Cancer Center